AAOS2018: Abaloparatide 80ug daily reduces rate of major NVFs in osteoporotic postmenopausal women

Study Type:Randomized Trial

OE Level Evidence:N/A

Journal Level of Evidence:N/A

Abaloparatide Reduced the Risk of Major Nonvertebral Fractures in Postmenopausal Women with Osteoporosis

Contributing Authors: PD Miller LA Fitzpatrick BH Mitlak G Williams MY Hu G Hattersley SV Bukata

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

CONFERENCE ACE REPORTS

This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.

Access conference website and list of abstracts.